ARTICLE | Clinical News
Glial derived neurotrophic factor: Phase II data
July 5, 2004 7:00 AM UTC
AMGN said in a double-blind Phase II trial in 34 patients, GDNF failed to meet the primary endpoint at 6 months. Patients who received daily infusions of 15 mg of GDNF into the putamen region of the b...